Overview

Study of Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With Unresectable Hepatocellular Carinoma

Status:
Not yet recruiting

Trial end date:
2025-03-31

Target enrollment:

Participant gender:

Summary

This is a prospective, open label, multi-center, interventional study to assess the safety and efficacy of Druvalumab plus Tremelimumab as first-line treatment in Chinese patients with unresectable hepatocellular carcinoma.

Phase:

Phase 3

Details

Lead Sponsor:

AstraZeneca

Treatments:

Durvalumab
Tremelimumab